HLB Panagene Co., Ltd. (KOSDAQ:046210)
1,450.00
-98.00 (-6.33%)
At close: Jun 19, 2026
HLB Panagene Revenue
HLB Panagene had revenue of 3.13B KRW in the quarter ending March 31, 2026, a decrease of -11.57%. This brings the company's revenue in the last twelve months to 14.64B, up 9.84% year-over-year. In the year 2025, HLB Panagene had annual revenue of 15.05B with 14.04% growth.
Revenue (ttm)
14.64B
Revenue Growth
+9.84%
P/S Ratio
4.51
Revenue / Employee
178.54M
Employees
82
Market Cap
66.02B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.05B | 1.85B | 14.04% |
| Dec 31, 2024 | 13.20B | 944.89M | 7.71% |
| Dec 31, 2023 | 12.25B | -16.39B | -57.22% |
| Dec 31, 2012 | 28.64B | -12.81B | -30.91% |
| Dec 31, 2011 | 41.45B | 7.41B | 21.77% |
| Dec 31, 2010 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2009 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2008 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GC Medical Science | 105.48B |
| Seoulin Bioscience | 78.58B |
| Dx & Vx | 28.48B |
| Cytogen | 26.84B |
| Protia | 16.25B |
| 3billion | 11.71B |
| GENINUS | 10.24B |
| Median Diagnostics | 7.86B |